ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2025
Rhea-AI Summary
ClearPoint Neuro (Nasdaq:CLPT) will participate in multiple investor conferences in Q4 2025.
Management will present and be available for in-person investor meetings at: UBS Global Healthcare Conference in Palm Beach Gardens, FL on November 10, 2025; Stifel Healthcare Conference in New York, NY on November 13, 2025; and the Piper Sandler Healthcare Conference in New York, NY on December 3, 2025. Registered investors can request onsite meetings with ClearPoint Neuro management.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CLPT declined 3.08%, reflecting a moderate negative market reaction. Argus tracked a peak move of +4.6% during that session. Argus tracked a trough of -12.0% from its starting point during tracking. Our momentum scanner triggered 43 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $17M from the company's valuation, bringing the market cap to $532M at that time. Trading volume was above average at 1.9x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / November 5, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it will participate in the following investor conferences:
2025 UBS Global Healthcare Conference - Palm Beach Gardens, FL
Presenting on Monday, November 10, 2025
2025 Stifel Healthcare Conference - New York, NY
Presenting on Thursday, November 13, 2025
37th Annual Piper Sandler Healthcare Conference - New York, NY
Presenting on Wednesday, December 3, 2025
Members of the ClearPoint Neuro management team will be onsite and available for in-person investor meetings who are registered to attend the various conferences.
About ClearPoint Neuro
ClearPoint Neuro is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company uniquely provides both established clinical products as well as pre-clinical development services for controlled drug and device delivery. The Company's flagship product, the ClearPoint Neuro Navigation System, has FDA clearance and is CE-marked. ClearPoint Neuro is engaged with healthcare and research centers in North America, Europe, Asia, and South America. The Company is also partnered with the most innovative pharmaceutical/biotech companies, academic centers, and contract research organizations, providing solutions for direct Central Nervous System delivery of therapeutics in pre-clinical studies and clinical trials worldwide. To date, thousands of procedures have been performed and supported by the Company's field-based clinical specialist team, which offers support and services to our customers and partners worldwide. For more information, please visit www.clearpointneuro.com.
Forward-Looking Statements
Statements in this press release and in the teleconference referenced above concerning the Company's plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, the size of total addressable markets or the market opportunity for the Company's products and services, the Company's expectation for revenues, operating expenses, the adequacy of cash and cash equivalent balances to support operations and meet future obligations, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. These forward-looking statements are based on management's current expectations and are subject to the risks inherent in the business, which may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: macroeconomic and inflationary conditions; regulatory and policy uncertainty; the introduction of or changes in tariffs, sanctions, or trade barriers; changes in monetary policy; geopolitical trends, such as protectionism and economic nationalism; future revenue from sales of the Company's products and services; the Company's ability to market, commercialize and achieve broader market acceptance for new products and services offered by the Company; the ability of our biologics and drug delivery partners to achieve commercial success, including their use of the Company's products and services in their delivery of therapies; the Company's ability to maintain its current relationships with biologics and drug delivery partners or enter into new relationships with such partners; the Company's expectations, projections and estimates regarding expenses, future revenue, capital requirements, and the availability of and the need for additional financing; the Company's ability to obtain additional funding to support its research and development programs; the ability of the Company to manage the growth of its business; the Company's ability to attract and retain its key employees; and risks inherent in the research, development, and regulatory approval of the Company's new products and the new therapeutic products of its biologics and drug delivery partners, including risks related to potential delays in the research, development, and regulatory approval process, and the ability to obtain and maintain regulatory approvals, manufacturing scale-up, supply chain and quality system readiness, intellectual property protection and freedom to operate, market acceptance and competitive dynamics. More detailed information on these and additional factors that could affect the Company's actual results are described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and the Company's Quarterly Report on Form 10-Q for the three months ended June 30, 2025, both of which have been filed with the Securities and Exchange Commission, and the Company's Quarterly Report on Form 10-Q for the three months ended September 30, 2025, which the Company intends to file with the Securities and Exchange Commission on or before November 14, 2025. The Company does not assume any obligation to update these forward-looking statements.
Contact:
Investor Relations
Danilo D'Alessandro, Chief Financial Officer
(888) 287-9109 ext. 3
ir@clearpointneuro.com
SOURCE: ClearPoint Neuro, Inc.
View the original press release on ACCESS Newswire
FAQ
When is ClearPoint Neuro (CLPT) presenting at the UBS Global Healthcare Conference?
What date will CLPT management present at the Stifel Healthcare Conference in 2025?
When is ClearPoint Neuro (CLPT) scheduled to present at the Piper Sandler Healthcare Conference?
Can investors meet ClearPoint Neuro management at the Q4 2025 conferences?
How can investors arrange a meeting with ClearPoint Neuro (CLPT) at these conferences?
Which conferences will ClearPoint Neuro (CLPT) attend in Q4 2025 and where are they located?
